Biogen Idec (BIIB) Could Be One To Watch On ImClone Bid

Watch Biogen Idec Inc. (Nasdaq: BIIB) on news that Bristol-Myers Squibb Co. (NYSE: BMY) offered to acquire ImClone (Nasdaq: IMCL) at a hefty premium of $60 per share.

Carl Icahn is a shareholder of BIIB and IMCL.

You May Also Be Interested In

• Irenic Capital opposes Independence Realty's Centerspace deal - Bloomberg
• Senior Iranian Official To Reuters: Iran Will Make No Concessions On Its Nuclear Program
• Saudi Arabia's East-west Pipeline Has Resumed Oil Exports - Bloomberg